A new scoring method may help predict who is at high risk of serious bleeding after a stroke, according to a study published in the August 2, 2017, online issue of Neurology.
For this new scoring method, researchers looked at people who were taking antiplatelet drugs after an ischaemic stroke or a transient ischaemic attack (TIA), or mini-stroke. These strokes were likely caused by clots that originated in the arteries to the brain or neck. Antiplatelet drugs include aspirin and clopidogrel. They did not include people whose blood clots may have originated in the heart and travelled to the brain, such as people with irregular heartbeats, including atrial fibrillation. The study did not look at anticoagulant drugs such as warfarin.
To develop the method, the researchers examined six large studies with a total of 43,112 participants who were followed for 94,833 years cumulatively. Of those, 1,530 people had a major bleeding event, which was defined as bleeding that was within the skull or resulted in death, hospital admission, or substantial disability. Overall, the risk of major bleeding in the first year was 1.9% percent. The three-year risk was 4.6%.
The researchers developed a score that can help predict the risk of bleeding. They found that 10 factors help predict the risk of bleeding:
- Male sex
- Taking aspirin with or without dipyridamole or taking aspirin-clopidogrel
- High stroke disability score
- Having a prior stroke
- High blood pressure
- Low body mass index
- Asian ethnicity
Age was the strongest predictor for major bleeding risk. The risk of bleeding ranged from 2% for people age 45 to 55 years with no additional risk factors to more than 10% for people age 75 to 85 years with multiple risk factors. Overall, 23,678 people were categorised as at low risk for major bleeding, 16,621 at medium risk and 2,813 at high risk.
“The increasing risk of bleeding with older age seems particularly important given the rising number of elderly people with a stroke or TIA, with around 30% of strokes occurring in people over 80,” said study author Nina A Hilkens of the University Medical Center Utrecht in the Netherlands.
The researchers also validated their prediction model by applying it to another large clinical trial.
“While the model may help identify people at high risk of major bleeding, it does not aim to guide treatment choices for antiplatelet drugs, as the risk of bleeding should always be balanced against the risk of recurrent stroke,” said Hilkens.
Limitations of the study include that the score was based on people involved in clinical trials, who may not be representative of all people who have strokes. Also, only trials that were published by 2010 were included in the study, and diagnosis and treatment of stroke has improved and changed since that time.